CN108351916A - 新生抗原分析 - Google Patents

新生抗原分析 Download PDF

Info

Publication number
CN108351916A
CN108351916A CN201680050906.1A CN201680050906A CN108351916A CN 108351916 A CN108351916 A CN 108351916A CN 201680050906 A CN201680050906 A CN 201680050906A CN 108351916 A CN108351916 A CN 108351916A
Authority
CN
China
Prior art keywords
neoantigens
candidate
candidate neoantigens
peptide
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680050906.1A
Other languages
English (en)
Chinese (zh)
Inventor
V·瓦库雷斯库
T·张
J·R·怀特
L·迪亚斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Personal Genome Diagnostics Inc
Original Assignee
Personal Genome Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Personal Genome Diagnostics Inc filed Critical Personal Genome Diagnostics Inc
Publication of CN108351916A publication Critical patent/CN108351916A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1068—Template (nucleic acid) mediated chemical library synthesis, e.g. chemical and enzymatical DNA-templated organic molecule synthesis, libraries prepared by non ribosomal polypeptide synthesis [NRPS], DNA/RNA-polymerase mediated polypeptide synthesis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1089—Design, preparation, screening or analysis of libraries using computer algorithms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/30—Detection of binding sites or motifs
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/40—Population genetics; Linkage disequilibrium
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
    • G16B35/20—Screening of libraries
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/20—Identification of molecular entities, parts thereof or of chemical compositions
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/50—Molecular design, e.g. of drugs
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/60—In silico combinatorial chemistry
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/70—Machine learning, data mining or chemometrics
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Theoretical Computer Science (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Biochemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Evolutionary Biology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Library & Information Science (AREA)
  • Computing Systems (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Plant Pathology (AREA)
  • Primary Health Care (AREA)
CN201680050906.1A 2015-07-14 2016-07-14 新生抗原分析 Pending CN108351916A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562192373P 2015-07-14 2015-07-14
US62/192,373 2015-07-14
PCT/US2016/042288 WO2017011660A1 (en) 2015-07-14 2016-07-14 Neoantigen analysis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202511758884.1A Division CN121963858A (en) 2015-07-14 2016-07-14 Neoantigen analysis

Publications (1)

Publication Number Publication Date
CN108351916A true CN108351916A (zh) 2018-07-31

Family

ID=57757739

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680050906.1A Pending CN108351916A (zh) 2015-07-14 2016-07-14 新生抗原分析

Country Status (6)

Country Link
US (3) US10563266B2 (https=)
EP (2) EP3323070B1 (https=)
JP (1) JP2018524008A (https=)
CN (1) CN108351916A (https=)
CA (2) CA3255210A1 (https=)
WO (1) WO2017011660A1 (https=)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109706065A (zh) * 2018-12-29 2019-05-03 深圳裕策生物科技有限公司 肿瘤新生抗原负荷检测装置及存储介质
CN110706742A (zh) * 2019-09-30 2020-01-17 中生康元生物科技(北京)有限公司 泛癌种肿瘤新生抗原高通量预测方法及其应用
CN111755067A (zh) * 2019-03-28 2020-10-09 格源致善(上海)生物科技有限公司 一种肿瘤新生抗原的筛选方法
CN112309502A (zh) * 2020-10-14 2021-02-02 深圳市新合生物医疗科技有限公司 一种计算肿瘤新抗原负荷的方法及系统
CN112771214A (zh) * 2018-09-27 2021-05-07 瓦西博迪公司 用于选择新表位的方法
CN113039612A (zh) * 2018-08-28 2021-06-25 赛科维有限两合公司 分级和/或选择肿瘤特异性新抗原的方法
CN113424264A (zh) * 2018-11-15 2021-09-21 Nouscom股份公司 用于生成个性化癌症疫苗的癌症突变选择

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016128060A1 (en) * 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
GB201516047D0 (en) 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method
US11514289B1 (en) 2016-03-09 2022-11-29 Freenome Holdings, Inc. Generating machine learning models using genetic data
JP7155470B2 (ja) * 2017-03-31 2022-10-19 エーシーティー ジェノミックス （アイピー） カンパニー リミテッド 免疫原性がん特異的エピトープのためのランク付けシステム
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
EP3688165A4 (en) 2017-09-25 2021-09-29 Nant Holdings IP, LLC VALIDATION OF THE PRESENTATION OF NEOEPITOPES
CN108388773B (zh) * 2018-02-01 2019-11-19 杭州纽安津生物科技有限公司 一种肿瘤新生抗原的鉴定方法
CN108491689B (zh) * 2018-02-01 2019-07-09 杭州纽安津生物科技有限公司 基于转录组的肿瘤新抗原鉴定方法
CN108796055B (zh) * 2018-06-12 2022-04-08 深圳裕策生物科技有限公司 基于二代测序的肿瘤新生抗原检测方法、装置和存储介质
EP3815091A4 (en) * 2018-06-29 2022-03-23 Rady Children's Hospital Research Center Method and system for sample identity assurance
EP3618071A1 (en) * 2018-08-28 2020-03-04 CeCaVa GmbH & Co. KG Methods for selecting tumor-specific neoantigens
CA3120200A1 (en) 2018-11-15 2020-05-22 Personal Genome Diagnostics Inc. Method of improving prediction of response for cancer patients treated with immunotherapy
CN109801678B (zh) * 2019-01-25 2023-07-25 上海鲸舟基因科技有限公司 基于全转录组的肿瘤抗原预测方法及其应用
CN111696628A (zh) * 2019-03-15 2020-09-22 痕准生物科技有限公司 新生抗原的鉴定方法
WO2020221783A1 (en) * 2019-04-29 2020-11-05 Vaccibody As Methods for pre-selection of neoepitopes
CN110600077B (zh) * 2019-08-29 2022-07-12 北京优迅医学检验实验室有限公司 肿瘤新抗原的预测方法及其应用
EP4062177A1 (en) * 2019-11-18 2022-09-28 Epivax Therapeutics, Inc. Improved compositions and methods for shared neo-epitope vaccines
CN114929899B (zh) * 2020-01-07 2026-03-10 韩国科学技术院 一种新抗原的筛选方法、系统及其用途
GB202006760D0 (en) * 2020-05-07 2020-06-24 Univ Helsinki Bioinformatics
JP2024508677A (ja) * 2021-02-05 2024-02-28 アマゾン テクノロジーズ インコーポレイテッド 個別化がんワクチン用ネオアンチゲンのランク付け
EP4330380A1 (en) 2021-04-30 2024-03-06 Tigen Pharma SA Single vessel expansion of lymphocytes
US12537072B1 (en) 2021-05-27 2026-01-27 Amazon Technologies, Inc. Immunogenic response prediction based on major histocompatibility complex (MHC) data
US20220383996A1 (en) * 2021-05-27 2022-12-01 Amazon Technologies, Inc. Assigning peptides to peptide groups for vaccine development
US12518851B2 (en) * 2021-09-07 2026-01-06 Nec Corporation Binding peptide generation for MHC class I proteins with deep reinforcement learning for immunotherapy decision making
JP2025541604A (ja) 2022-11-02 2025-12-22 ティゲン・ファーマ・ソシエテ・アノニム リンパ球の拡大
WO2024261339A1 (en) 2023-06-23 2024-12-26 Tigen Pharma Sa Lymphocyte-stimulatory matrix (lsm) and uses thereof for expansion of lymphocyte populations
WO2025049577A2 (en) * 2023-08-29 2025-03-06 Foundation Medicine, Inc. Neoantigen feature selection for prioritization of potential immunotherapy targets

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1889086A (zh) * 2006-07-20 2007-01-03 上海交通大学 交叉反应抗原计算机辅助筛选的方法
WO2007101227A2 (en) * 2006-02-27 2007-09-07 Arizona Board Of Regents For And On Behalf Of Arizona State University Identification and use of novopeptides for the treatment of cancer
WO2014052707A2 (en) * 2012-09-28 2014-04-03 The University Of Connecticut Identification of tumor-protective epitopes for the treatment of cancers

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US454A (en) 1837-11-04 Method obi constructing stoves
US5583024A (en) 1985-12-02 1996-12-10 The Regents Of The University Of California Recombinant expression of Coleoptera luciferase
US5750341A (en) 1995-04-17 1998-05-12 Lynx Therapeutics, Inc. DNA sequencing by parallel oligonucleotide extensions
GB9620209D0 (en) 1996-09-27 1996-11-13 Cemu Bioteknik Ab Method of sequencing DNA
US6054276A (en) 1998-02-23 2000-04-25 Macevicz; Stephen C. DNA restriction site mapping
US6223128B1 (en) 1998-06-29 2001-04-24 Dnstar, Inc. DNA sequence assembly system
US6787308B2 (en) 1998-07-30 2004-09-07 Solexa Ltd. Arrayed biomolecules and their use in sequencing
GB9901475D0 (en) 1999-01-22 1999-03-17 Pyrosequencing Ab A method of DNA sequencing
US6818395B1 (en) 1999-06-28 2004-11-16 California Institute Of Technology Methods and apparatus for analyzing polynucleotide sequences
WO2001023610A2 (en) 1999-09-29 2001-04-05 Solexa Ltd. Polynucleotide sequencing
US7809509B2 (en) 2001-05-08 2010-10-05 Ip Genesis, Inc. Comparative mapping and assembly of nucleic acid sequences
WO2005042781A2 (en) 2003-10-31 2005-05-12 Agencourt Personal Genomics Corporation Methods for producing a paired tag from a nucleic acid sequence and methods of use thereof
US7601499B2 (en) 2005-06-06 2009-10-13 454 Life Sciences Corporation Paired end sequencing
US7329860B2 (en) 2005-11-23 2008-02-12 Illumina, Inc. Confocal imaging methods and apparatus
US7754429B2 (en) 2006-10-06 2010-07-13 Illumina Cambridge Limited Method for pair-wise sequencing a plurity of target polynucleotides
US8262900B2 (en) 2006-12-14 2012-09-11 Life Technologies Corporation Methods and apparatus for measuring analytes using large scale FET arrays
US7835871B2 (en) 2007-01-26 2010-11-16 Illumina, Inc. Nucleic acid sequencing system and method
WO2008098014A2 (en) 2007-02-05 2008-08-14 Applied Biosystems, Llc System and methods for indel identification using short read sequencing
US8271206B2 (en) 2008-04-21 2012-09-18 Softgenetics Llc DNA sequence assembly methods of short reads
US20110257889A1 (en) 2010-02-24 2011-10-20 Pacific Biosciences Of California, Inc. Sequence assembly and consensus sequence determination
BR112012029066A2 (pt) * 2010-05-14 2020-09-01 The General Hospital Corporation composições e processos de identificação de neoantígenos específicos de tumor.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007101227A2 (en) * 2006-02-27 2007-09-07 Arizona Board Of Regents For And On Behalf Of Arizona State University Identification and use of novopeptides for the treatment of cancer
CN1889086A (zh) * 2006-07-20 2007-01-03 上海交通大学 交叉反应抗原计算机辅助筛选的方法
WO2014052707A2 (en) * 2012-09-28 2014-04-03 The University Of Connecticut Identification of tumor-protective epitopes for the treatment of cancers

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
J WHITE 等: "IDENTIFY AND PRIORITIZE CANDIDATE NEOANTIGENS FROM CANCER EXOME SEQUENCING RESULTS WITH UNMATCHED ACCURACY", 《HTTP://WWW.KROMOGEN.COM/DOCS/PGDX_IMMUNOSELECT.PDF》 *
MARIT M VAN BUUREN 等: "High sensitivity of cancer exome-based CD8 T cellneo-antigen identification", 《HTTPS://DOI.ORG/10.4161/ONCI.28836》 *
MOHINI RAJASAGI 等: "Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia", 《BLOOD》 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113039612A (zh) * 2018-08-28 2021-06-25 赛科维有限两合公司 分级和/或选择肿瘤特异性新抗原的方法
CN112771214A (zh) * 2018-09-27 2021-05-07 瓦西博迪公司 用于选择新表位的方法
CN112771214B (zh) * 2018-09-27 2025-06-13 耐考德治疗股份有限公司 用于选择新表位的方法
CN113424264A (zh) * 2018-11-15 2021-09-21 Nouscom股份公司 用于生成个性化癌症疫苗的癌症突变选择
CN113424264B (zh) * 2018-11-15 2024-04-12 Nouscom股份公司 用于生成个性化癌症疫苗的癌症突变选择
CN109706065A (zh) * 2018-12-29 2019-05-03 深圳裕策生物科技有限公司 肿瘤新生抗原负荷检测装置及存储介质
CN111755067A (zh) * 2019-03-28 2020-10-09 格源致善(上海)生物科技有限公司 一种肿瘤新生抗原的筛选方法
CN110706742A (zh) * 2019-09-30 2020-01-17 中生康元生物科技(北京)有限公司 泛癌种肿瘤新生抗原高通量预测方法及其应用
CN112309502A (zh) * 2020-10-14 2021-02-02 深圳市新合生物医疗科技有限公司 一种计算肿瘤新抗原负荷的方法及系统

Also Published As

Publication number Publication date
EP4407622A2 (en) 2024-07-31
US20250270656A1 (en) 2025-08-28
CA2992578A1 (en) 2017-01-19
EP3323070B1 (en) 2024-05-08
US10563266B2 (en) 2020-02-18
CA2992578C (en) 2025-09-09
EP3323070A4 (en) 2019-03-13
EP3323070A1 (en) 2018-05-23
WO2017011660A1 (en) 2017-01-19
US20200160939A1 (en) 2020-05-21
EP4407622A3 (en) 2025-01-08
JP2018524008A (ja) 2018-08-30
CA3255210A1 (en) 2025-03-19
US12331361B2 (en) 2025-06-17
US20170016075A1 (en) 2017-01-19

Similar Documents

Publication Publication Date Title
US20250270656A1 (en) Methods and systems for developing personalized vaccine by identification and prioritization of mutation-derived neoantigens
Fasolino et al. Single-cell multi-omics analysis of human pancreatic islets reveals novel cellular states in type 1 diabetes
Villani et al. Systems immunology: learning the rules of the immune system
Berest et al. Quantification of differential transcription factor activity and multiomics-based classification into activators and repressors: diffTF
Chang et al. Clinical application of amplicon-based next-generation sequencing in cancer
Alekseyev et al. A next-generation sequencing primer—how does it work and what can it do?
Bock Analysing and interpreting DNA methylation data
Morrissy et al. Spatial heterogeneity in medulloblastoma
Weber et al. Accurate detection of tumor-specific gene fusions reveals strongly immunogenic personal neo-antigens
Desai et al. Next‐generation sequencing: ready for the clinics?
ES2806728T3 (es) Resolución de fracciones de genoma usando recuentos de polimorfismos
JP2023504529A (ja) がん予測パイプラインにおけるｒｎａ発現コールを自動化するためのシステムおよび方法
JP2020110173A (ja) 染色体変化の非侵襲性評価のための方法およびプロセス
CA3129831A1 (en) An integrated machine-learning framework to estimate homologous recombination deficiency
JP2021521536A (ja) 生体試料の多検体アッセイのための機械学習実装
WO2016001760A2 (en) Determining mutation burden in circulating cell-free nucleic acid and associated risk of disease
JP2024512372A (ja) オフターゲットポリヌクレオチド配列決定データに基づく腫瘍の存在の検出
Du et al. Benchmarking spatial transcriptomics technologies with the multi-sample SpatialBenchVisium dataset
Patwekar et al. Genomic sequencing: Techniques, advancements, and the path ahead
Battaglia Neoantigen prediction from genomic and transcriptomic data
US20210202037A1 (en) Systems and methods for genomic and genetic analysis
EP3588506A1 (en) Systems and methods for genomic and genetic analysis
US20250137058A1 (en) Immunotherapy targeting
WO2024137664A9 (en) Methods for detecting glioblastoma in extracellular vesicles
Wen et al. Specific human leukocyte antigen class I genotypes predict prognosis in resected pancreatic adenocarcinoma: a retrospective cohort study

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1259317

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20180731